Journal Article

<i>In vitro</i> and <i>in vivo</i> activity of meropenem and sulbactam against a multidrug-resistant <i>Acinetobacter baumannii</i> strain

Wen-Chien Ko, Hsin-Chun Lee, Shyh-Ren Chiang, Jing-Jou Yan, Jiunn-Jong Wu, Chin-Li Lu and Yin-Ching Chuang

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 53, issue 2, pages 393-395
Published in print February 2004 | ISSN: 0305-7453
Published online February 2004 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dkh080
In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain

Show Summary Details

Preview

Objectives: The potential therapeutic role of meropenem combined with sulbactam against a clinical endemic isolate of multidrug-resistant Acinetobacter baumannii, Ab-153, was investigated.

Methods: The antimicrobial susceptibility of Ab-153 to various drugs was studied by the agar dilution method and Etest strips. The antibacterial activity of meropenem and sulbactam were investigated by a time–kill study in vitro and further examined for therapeutic efficacy in vivo in a murine model.

Results: In the time–kill study, at a concentration of 0.5 × MIC (4 mg/L) of meropenem, 1 × MIC (8 mg/L) of sulbactam and both in combination, only the combination demonstrated bactericidal effects and there was at least a 5 log10 reduction in bacterial colony counts after 48 h, compared with either drug alone. BALB/c mice infected with 2.1–2.6 × 107 cfu of Ab-153 were treated with 20 mg/kg meropenem every 8 h, 40 mg/kg sulbactam every 8 h or both in combination. The survival rate of mice in the combination group was significantly higher than that in the meropenem-treated or sulbactam-treated group (87% versus 35%, P = 0.0004; 87% versus 30%, P = 0.0002).

Conclusions: Meropenem in conjunction with sulbactam can exhibit more potent antimicrobial activity against Ab-153 than meropenem or sulbactam alone.

Keywords: Keywords: synergy, combination therapy, time–kill curves

Journal Article.  1969 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.